4.3.1 Sintesi e raccomandazioni - Biblioteca Medica

54. Roehrborn CG, Bruskewitz R, Nickel GC, Glickman S, Cox C, Anderson R, Kandzari
S, Herlihy R, Kornitzer G, Brown BT, Holtgrewe HL, Taylor A, Wang D, Waldstreicher
J for the PLESS Study Group. Eur Urol, 2000: 37, 528-536
55. Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, Fusilier HA,
Kozlowsky D, Kantor SD, Johnson EL, Wang DZ and Waldstreicher J for the PLESS
Study Group. Effect of finasteride on bother and other health-related quality of life
aspects associated with benign prostatic hyperplasia. Urology, 1999: 54, 670-678
56. Wessels H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, Herlihi R, Fitch W,
Labasky R, Auerbach S, Parra R, Rajfer J, Culbertson J, Lee M, Bach MA and
Waldstreicher J for the PLESS Study Group. Incidence and severity of sexual adverse
experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.
Urology, 2003: 61, 579-584
57. Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M,
Geller J, Imperato-McGinley J, Andriole GL, Bruskewitz RC, Walsh PC, Bartsch G,
Nacey JN, Shah S, Pappas F, Ko A, Cook T, Stoner E and Waldstreicher J, for the
Finasteride Study Group. Long -term 6-year experience with Finasteride in patients
with benign prostatic hyperplasia. Urology, 2003: 61, 791-796
58. Thompson IM, Goodman PJ, Tangen CM, Scott Lucia M, Miller GJ, Ford LG, Lieber
MM, Cespedes D, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM,
Crowley JJ, Coltman CA. The influence of Finasteride on the development of prostate
cancer. N Engl J Med, 2003: 349, 215-224
59. Roehrborn CG, Boyle P, Nickel JC, Hoefner K and Andriole G, on behalf of the
ARIA3001, ARIA3002, and ARIA3003 STUDY INVESTIGATORS. Efficacy and
safety of a dula inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with
benign prostatic hyperplasia. Urology, 2002: 60, 434-441
60. Andriole GL, Kirby R. Safety and tolarability of the dual 5alpha-reductase inhibitor
Dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol, 2003: 44, 82-
88
61. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate
and postoperative complications. A cooperative study of 13 participating
institutions evaluating 3885 patients. J Urol, 1989: 141, 243-247
62. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A
comparison of transurethral surgery with watchful waitng for moderate symptoms of
benign prostatic hyperplasia: The Veteran Affairs Cooperative Study Group on
Transurethral Resection of the Prostate. N Engl J Med, 1995: 332, 75-79
63. Soderdahl DW, Knight RW and Hansberry KL. Erectile dysfunction following
transurethral resection of the prostate. J Urol, 1996: 156, 1354-1360
64. Gilling PJ, Mackey M, Cresswell M, Kennett K, Kabalin JN and Fraundorfer MR.
Holmium laser versus transurethral resection of the prostate: a randomized prospective
trial with 1-year followup. J Urol, 1999: 162, 1640-1644
65. Arai Y, Aoki Y, Okubo K, Maeda H, Terada N, Matsuta Y, Maekawa S and Ogura K.
Impact of interventional therapy for benign prostatic hyperplasia on quality of life and
sexual function: a prospective study. J Urol, 2000: 164, 1206-1211
249